KR20070050624A - Healthy and functional food for constipation improvement - Google Patents
Healthy and functional food for constipation improvement Download PDFInfo
- Publication number
- KR20070050624A KR20070050624A KR1020050108050A KR20050108050A KR20070050624A KR 20070050624 A KR20070050624 A KR 20070050624A KR 1020050108050 A KR1020050108050 A KR 1020050108050A KR 20050108050 A KR20050108050 A KR 20050108050A KR 20070050624 A KR20070050624 A KR 20070050624A
- Authority
- KR
- South Korea
- Prior art keywords
- constipation
- red ginseng
- extract
- functional food
- jujube
- Prior art date
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 98
- 235000013376 functional food Nutrition 0.000 title claims abstract description 25
- 230000006872 improvement Effects 0.000 title claims abstract description 18
- 235000001497 healthy food Nutrition 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 51
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 50
- 230000001684 chronic effect Effects 0.000 claims abstract description 41
- 230000036541 health Effects 0.000 claims abstract description 26
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 21
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 21
- 241000287828 Gallus gallus Species 0.000 claims abstract description 21
- 235000006533 astragalus Nutrition 0.000 claims abstract description 18
- 241001061264 Astragalus Species 0.000 claims abstract description 17
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 17
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 17
- 210000004233 talus Anatomy 0.000 claims abstract description 17
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 13
- 229940010454 licorice Drugs 0.000 claims abstract description 13
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 8
- 229940069445 licorice extract Drugs 0.000 claims abstract description 7
- 239000010865 sewage Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 8
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 241001247821 Ziziphus Species 0.000 description 12
- 240000004371 Panax ginseng Species 0.000 description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 description 11
- 235000008434 ginseng Nutrition 0.000 description 11
- 235000020710 ginseng extract Nutrition 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 235000013305 food Nutrition 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 230000037213 diet Effects 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 5
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical group 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 241000331432 Cynanchum wilfordii Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 229910001388 sodium aluminate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 홍삼 추출물의 증진된 변비 개선 기능을 갖는 건강기능식품에 관한 것으로서, 보다 구체적으로는 홍삼, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물을 함유하며, 특히 만성변비의 개선 기능을 갖는 건강기능식품에 관한 것이다.The present invention relates to a health functional food having an improved constipation improvement function of red ginseng extract, more specifically, containing red ginseng, tangui, white sewage, safflower seed, broiler, astragalus, jujube and licorice extract, in particular to improve chronic constipation It relates to a health functional food having a function.
변비, 홍삼, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추, 감초 Constipation, Red ginseng, Angelica, Baekhasuo, Safflower seed, Broiler, Astragalus, Jujube, Licorice
Description
본 발명은 홍삼 추출물의 증진된 변비의 개선 기능, 특히 만성변비의 개선 기능을 갖는 건강기능식품에 관한 것이다.The present invention relates to a health functional food having an improved function of improved constipation of red ginseng extract, in particular chronic constipation.
근래에 들어서, 식생활수준의 급속한 향상으로 인해 고지방과 고단백질이 함유된 육류와 인스턴트식품 등의 고칼로리 식품의 섭취가 늘어난 반면에 야채나 섬유질을 함유하는 식품의 섭취가 감소됨으로써 성인병과 비만환자가 날로 증가되고 있는 추세에 있음은 잘 알려진 사실이다.In recent years, the rapid increase in dietary standards has led to an increase in the consumption of high-calorie foods such as meats and instant foods containing high fat and high protein, while reducing the intake of foods containing vegetables and fiber, resulting in reduced adult and obese patients. It is a well known fact that the trend is increasing day by day.
일반적으로 만성 기능성 변비의 정의는 과거 12개월 동안 반복되지는 않지만 최소한 12주 이상의 기간 동안 다음 5가지 증상 즉, ⑴ 힘주기, ⑵ 고형변이나 덩어리변, ⑶ 불완전한 배출감각, ⑷ 배변 폐쇄감, ⑸ 1주일에 2회 이하의 배변, 중에서 2개 이상을 호소하는 경우로 하고 있다.In general, the definition of chronic functional constipation is not repeated in the past 12 months, but for at least 12 weeks or more, the following five symptoms are: ⑴ force, ⑵ solid or lumpy stools, ⑶ incomplete discharge sensation, ⑷ defecation sensation, ⑸ 1 It is assumed that two or more bowel movements are complained twice a week.
변비는 사회생활에 지장을 주지 않는 정도의 비교적 가벼운 정도부터 정상적 인 일상생활을 어렵게 하는 심한 중증의 경우까지 다양한 양상을 갖는 만성 소화기 질환이다. 최근 사회, 경제적인 여건의 서구화와 더불어 환자의 수가 증가할 뿐만 아니라 불편을 호소하는 정도가 심화되는 등의 변화를 보이고 있다.Constipation is a chronic gastrointestinal disease with a variety of symptoms ranging from relatively mild to moderate social life to severely severe cases that make normal daily life difficult. Recently, the number of patients has increased as well as the number of patients has increased along with the westernization of social and economic conditions.
또한, 과민성장증후군은 그 원인이 밝혀지지 않은 상태에 있으나 이와 관련된 병태생리로는 내장과 감각, 운동 이상 및 사회적인 인자들이 함께 작용하는 것으로 알려져 있다. 주된 증상에 따라서 변비형과 설사형으로 구분하고 있으며 치료는 역시 주된 증상에 따라서 치료하고 있다.In addition, the cause of irritable growth syndrome is unknown, but the pathophysiology associated with it is known that the internal organs, sensory, motor abnormalities and social factors work together. It is divided into constipation type and diarrhea type according to the main symptoms, and treatment is also treated according to the main symptoms.
따라서 과민성장증후군의 변비형과 기능성변비에는 그 치료에 큰 차이가 없다고 할 수 있다. 이에 변비를 6개의 아형으로 구분하여 단순형, 과민성장증후군형, 지연된 장통과, 배변곤란, 분변박힘과 위폐쇄증으로 나누고 있다.Therefore, there is no significant difference in the treatment between constipation type and functional constipation. The constipation is divided into six subtypes and divided into simple type, hypersensitivity syndrome, delayed intestinal pain, difficulty in defecation, fecal constriction and gastric obstruction.
변비의 일반적인 원인은 식생활의 문제점, 즉 섬유소의 섭취가 너무 적거나 음식의 양이 적은 경우 그리고 배변욕구를 무시하거나 억제한 경우와 신체적인 운동이 너무 제한된 경우들이다. 그 밖에 2차적인 변비의 원인은 장운동을 떨어뜨리는 약재의 사용, 각종 내분비 질환, 신경질환 및 정신적인 문제를 가진 경우들이다. 물론 변비의 원인이 될 수 있는 2차적인 변비의 경우는 그 것을 찾아서 제거하면 되겠지만 대부분의 경우는 소위 "단순형 변비"이거나 "과민성장증후군"의 한 형태로서의 변비가 많으므로 그 치료방법은 동일하다고 할 수 있다.Common causes of constipation are problems with diet, such as low intake of fiber or low amounts of food, neglected or suppressed bowel movements, and too limited physical exercise. Other causes of secondary constipation are the use of medicinal herbs that reduce bowel movement, various endocrine diseases, neurological diseases and mental problems. Of course, secondary constipation, which may be the cause of constipation, can be removed by finding it, but in most cases, so-called "simple constipation" or "hypersensitivity syndrome" as a form of constipation, so the treatment method is the same can do.
변비의 치료를 위해서는 생활양식의 변화, 정신신경적인 보조 요법, 식생활 개선 및 수분섭취의 증대 등의 일반적인 치료와 함께 각종 변비치료제를 사용하게 된다. 변비치료제의 종류에는 몇 주 동안의 치료 후에 그 효과를 기대할 수 있는 섬유소제제, 2~3일 후에 효과를 기대할 수 있는 삼투성 변비 약제 및 1일 이내에 효과를 기대할 수 있는 자극성제제 들이 있다.For the treatment of constipation, various constipation treatments are used along with general treatments, such as lifestyle changes, psychological adjuvant therapy, improved diet and increased fluid intake. Types of constipation treatments include fibrin preparations that can be expected after several weeks of treatment, osmotic constipation agents that can be expected after 2-3 days, and irritant agents that can be expected within 1 day.
인삼은 각종 질환에 대한 예방과 치료효과를 가지는 것으로 잘 알려져 왔으며, 특히 소화기계에 대한 효과가 분명하여 소화 기능의 개선 및 대장운동을 촉진하는 것으로 알려져 있어, 변비치료용 생약조성물로 이용되고 있다. 예를들면, 대한민국 특허등록 제149389호에는 귤껍질 유효성분 추출액을 주성분으로 하며 인삼, 오미자, 백반, 감초, 살구씨 및 구기자를 함유하는 변비치료용 생약조성물이 공지되어 있다.Ginseng has been well known to have a prophylactic and therapeutic effect against various diseases, and in particular, the effect on the digestive system is well known to promote the improvement of digestive function and colon movement, and is used as a herbal composition for treating constipation. For example, Korean Patent Registration No. 149389 discloses a herbal composition for treating constipation containing ginseng, schisandra chinensis, alum, licorice, apricot seed and goji berry as its main ingredient.
또한, 홍삼은 인삼 즉, 수삼(수분 약 75%)이나 백삼(수삼을 그대로 건조: 수분 약 12%)과는 다르게 일정한 온도 조건하에서 수증기로 찐 후 건조하여 인삼의 녹말을 호화한 것으로서, 백삼과 같이 배당체(glycosides)를 함유하나 백삼의 사포닌 성분인 진세노사이드 Re가 20번 탄소에서 글리코실(glycosyl) 잔기가 이탈되거나 수산기가 이성화되어 홍삼 특유의 사포닌으로 변환됨으로서 백삼 산성다당체와는 상이한 물질인 홍삼산성 다당체가 생성되며, 아답토겐(adaptogen) 효과가 있어 주위 환경으로부터 오는 각종 유해작용인 누병(淚病), 각종 스트레스 등에 대해 방어능력을 증가시켜 생체가 보다 쉽게 적응하도록 하는 능력이 있는 물질을 함유하고 있어 인삼과 서로 상이한 물질로 취급되고 있다.Also, unlike ginseng, that is, ginseng (about 75% moisture) or white ginseng (dry ginseng as it is: about 12% moisture), red ginseng is steamed with steam under certain temperature conditions and dried to make starch of ginseng deluxe. Ginsenoside Re, which contains glycosides but is a saponin component of white ginseng, is a substance different from white ginseng polysaccharides by decomposing glycosyl residues at 20 carbons or isomerization by converting hydroxyl groups into saponins unique to red ginseng. Red ginseng acid polysaccharide is produced, and has an adaptogen effect, which increases the ability to defend against various diseases such as fistula, stress, etc. It contains and is treated as a different material from ginseng.
홍삼 역시 변비 치료용 생약조성물로 이용된 예가 공지되어 있는데, 예를 들 면, 대한민국 공개특허 제2004-63430호에는 변비 개선효과가 있는 알로에 및 다시마에 홍삼, 노두, 마 및 백출 추출물을 함유하는 변비 개선용 조성물이 공지되어 있다.Red ginseng is also known to be used as a herbal composition for the treatment of constipation, for example, Korean Patent Laid-Open No. 2004-63430, Constipation containing red ginseng, outcrops, hemp and baekchul extracts in aloe and kelp with a constipation improving effect Improvement compositions are known.
이에 본 발명자는 홍삼의 기능을 연구하던 중 인삼 추출물과는 달리 홍삼 추출물은 장관 기능에 있어 훨씬 효과적임을 알게 되었다. 이에 착안하여 보다 효과적인 변비 개선 기능을 갖는 홍삼 함유 생약조성물을 연구하게 되었다.Thus, the present inventors found that red ginseng extract is much more effective in intestinal function than ginseng extract while studying the function of red ginseng. With this in mind, we studied a red ginseng-containing herbal composition with more effective constipation improving function.
한편, 생약재를 이용하여 변비를 해결하고자 많은 연구가 진행되어 왔다.Meanwhile, many studies have been conducted to solve constipation using herbal medicines.
대한민국 특허등록 제435825호에는 당귀, 지실, 하수오, 백출, 천궁, 진피, 생강, 감초 및 육계를 함유하는 변비치료용 생약조성물이 기재되어 있으며,Korean Patent Registration No. 435825 describes a herbal composition for the treatment of constipation containing Angelica, Jisil, Sewao, Baekchul, Cheongung, Dermis, Ginger, Licorice and Broiler.
대한민국 특허등록 제506824호에는 장기능 및 변비 질환 개선 효과를 갖는 생약조성물로 무, 차, 당근, 진피, 청피, 무화과, 양파, 오매 및 살구추출물을 함유하는 생약조성물이 기재되어 있다.Korean Patent Registration No. 506824 describes a herbal composition containing radish, tea, carrot, dermis, green skin, fig, onion, ume and apricot extract as a herbal composition having an effect of improving bowel function and constipation disease.
또한 대한민국 특허등록 제376307호에는 당귀, 황기, 백작, 백출, 산사옥, 계피, 구기자, 산수유 및 감초를 함유하는 변비 치료용 건강식품 조성물이 공지되어 있으며,In addition, Korean Patent Registration No. 376307 discloses a health food composition for treating constipation containing Angelica, Astragalus, Count, Baekchul, Hawthorn, Cinnamon, Wolfberry, Cornus and Licorice.
대한민국 특허등록 제451665호에는 홍화씨를 주성분으로 하며, 멸치, 다시 마, 대추, 생강, 흑두, 솔잎, 마늘, 토사자, 우슬, 오가피, 두충, 녹각, 감초, 방기, 하수오, 오미자, 지황, 지모, 백분자, 천초, 지골피, 오배자, 계지, 진피, 갈근, 백출 및 창출을 첨가한 생약 조성물이 골다공증, 변비, 고혈압, 탈모 및 인체의 산성화 등의 발생을 방지하는 건강기능식품으로 공지되어 있다.Korean Patent Registration No. 451665 is based on safflower seed, anchovies, kelp, jujube, ginger, black bean, pine needles, garlic, earth and sand, dew, cucumber skin, tofu, green tea, licorice, Banggi, sewao, Schisandra chinensis, jihwang, jimo, Herbal medicine composition with added white molecule, cheoncho, phalanx, gall bladder, cinnamon, dermis, reed, white extract and creation is known as a health functional food that prevents the occurrence of osteoporosis, constipation, high blood pressure, hair loss and acidification of the human body.
그러나, 이와 같이 천연식물을 이용하여 변비를 해결하고자 많은 연구가 진행되어 왔음에도 불구하고 반성변비는 그 치료는 매우 어렵고 불완전하다.However, even though many studies have been conducted to solve constipation using natural plants as described above, reflective constipation is very difficult and incomplete treatment.
상기 종래 기술에 이용된 많은 생약재를 연구하던 중에 본 발명자는 홍삼이 갖는 변비 개선 기능을 증진 시킬 수 있는 생약재로 당귀, 홍화씨, 백하수오, 육계 및 황기를 주목하였다.While studying a number of herbal medicines used in the prior art, the inventors noted that Angelica, safflower seed, Baek Ha Shou, broiler and Astragalus as herbal medicines to enhance the constipation improvement function of red ginseng.
당귀는 산형과에 속하는 숙근초(宿根草)로 참당귀 뿌리가 약재로 쓰이는데, 변비시에 사용하면 배변이 쉬워 변비 치료용에 많이 사용되고 있다.Angelica is a medicinal root (초 根草) belonging to the mountain-shaped family, and the root of the true donkey is used as a medicinal herb.
백하수오(白何首烏)는 큰조롱(Cynanchum wilfordii)의 뿌리로서 강장제로 사용되며, 홍화씨는 종래 뼈를 튼튼하게 하고, 부러진 뼈를 붙이며, 골다공증을 치료하는 데 효능이 있는 것으로 알려져 있으며, 한방에서는 부인병, 통경, 복통 등에 사용하였고, 콜레스테롤 과다에 의한 동맥경화증의 예방과 치료에 좋은 것으로 알려져 있었으며, 육계(肉桂)는 약용으로는 발한, 해열, 진통, 건위제 등으로 자주 사용되며, 황기(Astragalus membranaceus Bunge)는 뿌리에서 2',4'-디히드록시- 5'6'-디메톡시이소플라반, 5,4'-디옥시-3, 7-디메톡시플라본, 분자식 C16H12O5인 플라보노이드, 쿠마타게닌이 분리되었으며, 뿌리에는 또한 β-시토스테롤, 과당, 포도당, 점액질과 알칼로이드, 콜린, 베타인, 리놀산, 리놀레인산과 아미노산들로 로이찐(16㎎%), 글리찐(24㎎%), 세린(28㎎%), 알라닌(55㎎%), 글루타민산(77㎎%), 아르기닌(83㎎%), γ-아미노버터산(24~66㎎%)이 함유되어 있으며, 진정작용, 혈압강하작용, 혈관확장작용이 있어 고혈압, 혈액순환이 파괴된 만성적인 심장혈관장애, 급성 및 만성 심장병에 유용한 것으로 알려져 있으며, 한방에서는 강정제, 강장제, 이뇨제 등으로 사용하였다.Baek Ha Shou (白 何首烏) is used as a tonic as the root of a large mock ( Cynanchum wilfordii ), and safflower seeds are known to be effective in strengthening bones, attaching broken bones, and treating osteoporosis. It has been used to prevent and treat arteriosclerosis caused by excessive cholesterol, and broilers are frequently used as medicinal sweats, fever, analgesics, and sensitizers. Astragalus membranaceus Bunge ) Is flavonoid with 2 ', 4'-dihydroxy-5'6'-dimethoxyisoflavan, 5,4'-dioxy-3, 7-dimethoxyflavone, molecular formula C 16 H 12 O 5 at the root , Kumatagenine has been isolated, and roots also contain β-sitosterol, fructose, glucose, mucus and alkaloids, choline, betaine, linoleic acid, linoleic acid and amino acids, leucine (16 mg%), and glycine (24 mg%). ), Serine (28 mg%), Allah (55mg%), glutamic acid (77mg%), arginine (83mg%), and γ-aminobutyric acid (24-66mg%) are contained, sedation, blood pressure lowering, vasodilation, hypertension In addition, it is known to be useful for chronic cardiovascular disorders, acute and chronic heart disease in which blood circulation is destroyed, and in oriental medicine, it was used as a tonic, tonic, and diuretic.
그러나, 상기 백하수오, 홍화씨, 육계 및 황기는 변비 증상의 개선 기능을 갖는 생약조성물에 사용된 예는 있으나, 그 자체가 변비 증상의 개선 효과가 있는지는 보고된 바 없다.However, although there are examples used in the herbal composition having the function of improving constipation symptoms, Baek Sewao, safflower seeds, broilers and Astragalus have not been reported to have an effect of improving constipation symptoms themselves.
본 발명자는 종래 변비 개선에 이용되었던 많은 생약재 중에서, 당귀, 백하수오, 홍화씨, 육계 및 황기를 홍삼 추출물과 혼합한 혼합조성물이 보다 증진된 홍삼 추출물의 변비 증상의 개선 기능, 특히 만성변비를 개선시킬 수 있는 기능을 가짐을 발견하고 본 발명을 완성하였다.The inventors have improved the constipation symptoms, especially chronic constipation of red ginseng extract, which is a mixed composition of the Angelica, Baek Sewao, safflower seed, broiler, and Astragalus with red ginseng extract, among many herbal medicines that have been used to improve constipation in the past. The present invention has been found to have the capability of being capable of.
본 발명은 보다 증진된 홍삼 추출물의 변비 증상의 개선 기능을 갖는 건강기 능식품 조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a health functional food composition having an improved function of constipation symptoms of red ginseng extract.
또한 본 발명은 특히 홍삼을 함유하며 만성변비를 개선시킬 수 있는 기능을 갖는 건강기능식품 조성물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a health functional food composition containing red ginseng and having a function of improving chronic constipation.
상기의 목적을 달성하기 위하여 본 발명은 홍삼, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물을 함유하며 증진된 변비 개선 효과, 특히 만성변비 증상을 개선할 수 있는 건강기능식품을 제공한다.In order to achieve the above object, the present invention contains a red ginseng, Angelica, baekshou, safflower seed, broiler, Astragalus, jujube and licorice extract and provides a health functional food that can improve the constipation improvement effect, especially chronic constipation symptoms do.
홍삼 추출물의 증진된 만성변비의 개선 기능을 갖는 건강기능식품에 관한 것이다.It relates to a health functional food having an improved function of enhanced chronic constipation of red ginseng extract.
본 발명에 있어서 홍삼추출물은 별도로 제조하거나 또는 공지된 방법에 의해 제조되어 있는 홍삼추출물을 사용할 수 있다.In the present invention, the red ginseng extract may be prepared separately or a red ginseng extract prepared by a known method may be used.
본 발명은 홍삼 추출물의 증진된 만성변비의 개선 기능을 갖도록 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물 혼합한 것으로서, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물은 물 또는 알코올성 수용액으로 추출한다. 그러나 잘 알려져 있는 바와 같이 알코올성 수용액으로서 메탄올과 같이 인체에 유해한 것은 사용하지 않는 것이 바람직하다.The present invention is a mixture of Angelica, White Sewage, Safflower Seed, Broiler, Astragalus, Jujube and Licorice extracts to have an improved chronic constipation of red ginseng extract. Extract with water or alcoholic aqueous solution. However, as is well known, it is preferable not to use an alcoholic aqueous solution which is harmful to human body such as methanol.
본 발명은 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물을 적절한 배합비에 따라 각각 또는 혼합하여 추출을 할 수 있으며, 홍삼 5~15중량%, 당귀 10~44.9중량%, 백하수오 10~15중량%, 홍화씨 10~15중량%, 육계 10~15중량%, 황기 10~15중량%, 대추 10~15중량% 및 감초 0.1~0.5중량%로 혼합된다.The present invention can be extracted by mixing each or mixed with Angelica, Baekshou, safflower seed, broiler, Astragalus, jujube and licorice extract according to the appropriate blending ratio, red ginseng 5-15% by weight, Angelica 10-44.9% by weight, Baekshou 10 ~ 15% by weight, safflower seed 10-15% by weight, broiler 10-15% by weight, Astragalus 10-15% by weight, jujube 10-15% by weight and licorice 0.1-0.5% by weight.
상기 본 발명에 따른 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초의 혼합 추출물은 혼합되어 80~100℃에서 1~5 시간 열수 추출하여 감압 농축시켜 추출물을 제조하며, 에탄올로 추출할 때는 60~80℃에서 1~5 시간 추출하여 감압 농축시켜 추출물을 제조한다.The mixed extracts of Angelica, Baekshou, Safflower, Broiler, Astragalus, Jujube and Licorice according to the present invention are mixed and extracted by hot water extraction at 80-100 ° C. for 1-5 hours to produce an extract under reduced pressure, and extracted with ethanol. Extract 1 to 5 hours at 60 ~ 80 ℃ to concentrate under reduced pressure to prepare an extract.
상기 혼합추출물은 미리 준비된 홍삼추출물과 혼합한 후, 혼합되어 음료용의 액상 건강기능식품으로 제조 될 수 있으며, 각 추출물을 동결건조를 하거나 진공건조, 바람직하게는 동결건조를 하여 분말엑스로 제조한 후 분말엑스 형태의 건강기능식품 조성물로 제조 될 수 있다.The mixed extract may be mixed with a red ginseng extract prepared in advance, and then mixed and prepared as a liquid health functional food for a drink. Each extract may be lyophilized or vacuum dried, preferably lyophilized to prepare a powder extract. After the powder can be prepared as a dietary supplement composition of the form.
본 발명은 변비 증상을 개선하기 위한 식품 또는 음료에 첨가될 수도 있으며, 파우치, 치어팩 또는 병 형태의 음료형태, 환제, 캡슐제 또는 정제 형태 등으로 제품화될 수도 있다.The present invention may be added to food or beverages for improving constipation symptoms, and may be commercialized in the form of beverages, pills, capsules or tablets in the form of pouches, cheer packs or bottles.
일반적으로 본 발명에 따른 건강기능식품은 전체 식품 중량의 0.01 내지 80중량%로 가할 수 있으며, 건강음료 조성물은 50㎖를 기준으로 0.02 내지 30g, 바람직하게는 0.3 내지 5g의 비율로 첨가할 수 있다.In general, the health functional food according to the present invention may be added at 0.01 to 80% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 30g, preferably 0.3 to 5g based on 50ml. .
또한 본 발명은 보다 향상된 변비 개선 기능과 감미효과를 위하여 상기 혼합추출물 또는 혼합분말엑스에 올리고당 또는 식이섬유를 추가로 포함할 수 있다.In addition, the present invention may further include oligosaccharides or dietary fiber in the mixed extract or mixed powder extract for improved constipation improving function and sweetening effect.
올리고당은 포도당, 과당, 갈락토즈와 같은 단당류가 2내지 8개 결합한 일종의 탄수화물이다. 또한 섭취시 장내 소화효소에 의해서 분해되지 않고 대장까지 도달하여 그 곳에 서식하고 있는 비피더스균을 비롯한 장내 유용한 세균에 이용되며 유해 세균 또는 병원성 세균의 증식을 억제하는 기능을 가진다. 올리고당의 종류로는 대두올리고당, 프락토올리고당, 갈락토올리고당, 이소말토올리고당 등이 있으며 모두 설탕보다는 낮은 감미도를 갖는다.Oligosaccharides are a type of carbohydrate in which two to eight monosaccharides such as glucose, fructose and galactose are combined. It is also used for intestinal useful bacteria, including bifidus bacteria, which are inhabited by the intestine without being degraded by intestinal digestive enzymes when ingested, and have the function of inhibiting the proliferation of harmful or pathogenic bacteria. Oligosaccharides include soy oligosaccharides, fructooligosaccharides, galactooligosaccharides and isomaltooligosaccharides, all of which have lower sweetness than sugar.
식이섬유는 인간의 소화효소에 의해서 가수분해되지 않는 식품 중 난소화성성분의 총체로서 식물성에 속하는 수용성 식이섬유로는 펙틴, 검류(gums), 해조다당류 및 폴리덱스트로스가 있으며, 불용성으로는 셀룰로오스, 헤미셀룰로오스 및 리그닌이 있고 동물성으로는 키틴 및 키토산이 있다. 본 발명에서는 이들 식이섬유가 모두 사용할 수 있지만 대한민국 식품공전에 등재되어 있는 폴리덱스트로스를 사용하는 것이 바람직하다.Dietary fiber is a total of indigestible constituents in foods that are not hydrolyzed by human digestive enzymes. Water-soluble dietary fiber belonging to the plant includes pectin, gums, seaweed polysaccharides and polydextrose, and insoluble cellulose, hemicellulose and Lignin and animals include chitin and chitosan. In the present invention, all of these dietary fibers may be used, but it is preferable to use polydextrose listed in the Korean Food Code.
상기 올리고당 및 식이섬유의 첨가량은 본 발명에 따른 건강기능식품의 맛을 고려하고 당 분야에서 쉽게 정할 수 있다. 다만, 올리고당의 경우 건강기능식품 전체 중량의 40중량%를 넘지 않는 범위 내에서, 식이섬유의 경우 50중량%를 넘지 않는 범위 내에서 첨가하는 것이 바람직하며, 이 경우 보다 향상된 변비 개선 기능을 갖는 건강기능식품을 제공할 수 있다.The addition amount of the oligosaccharides and dietary fiber may be easily determined in the art considering the taste of the health functional food according to the present invention. However, in the case of oligosaccharide, it is preferable to add it within the range not exceeding 40% by weight of the total weight of the health functional food, and in the range not exceeding 50% by weight of the dietary fiber, in which case the health with improved constipation improvement function Functional food can be provided.
또한, 본 발명은 통상의 부형제, 향료, 감미료, 소취제 등의 첨가제를 건강기능식품 전체의 2중량%를 넘지 않는 범위 내에서 추가로 포함할 수 있다.In addition, the present invention may further include additives such as conventional excipients, fragrances, sweeteners, deodorants, etc. within the range not more than 2% by weight of the whole health functional food.
본 발명에 있어서 소취제로서는 샴피니온 추출물이 바람직한데 최근에 샴피니온은 아미노산, 폴리페놀, 후라보노이드 등의 성분이 암모니아와 아민류 등 냄새가 나는 성분과 결합하여 중화시키거나 무취화시키고, 다당류는 화학구조속의 악취성분을 무취화시키는 것으로 알려져 있으며, 또한 장내의 비피더스균을 증가시켜 장의 움직임에 도움을 주는 것으로 알려져 있어 본 발명에 적용하는 것이 바람직하다.In the present invention, as a deodorant, a champinion extract is preferred. Recently, champinions are neutralized or odorized by combining components such as amino acids, polyphenols, and flavonoids with odorous components such as ammonia and amines. It is known to deodorize the odor component in the structure, and is known to assist intestinal movement by increasing bifidus in the intestine.
본 발명은 복용이 편리하도록 분말화한 후 통상의 방법에 따라 캡슐제, 정제 또는 환제 등의 형태로 제형화 할 수 있으며, 또는 액상 형태로서 음료 등의 형태로 제형화 할 수도 있다.The present invention may be formulated in the form of capsules, tablets or pills according to a conventional method after powdering for convenient taking, or may be formulated in the form of a beverage or the like as a liquid form.
이하 본 발명을 하기 실시예 및 실험예를 통하여 상세히 설명하나, 본 발명이 여기에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to the following Examples and Experimental Examples, but the present invention is not limited thereto.
실시예 1. 홍삼 추출물의 제조 Example 1 Preparation of Red Ginseng Extract
본 실시예는 대한민국 공개특허공보 제1998-19946호에 기재된 방법에 따라 홍삼을 제조된 홍삼 100g을 100℃에서 2시간 열수 추출하고 얻어진 추출액을 감압 농축(수분 40%) 하여 홍삼 추출물을 제조하였다.In this embodiment, according to the method described in Korean Patent Laid-Open Publication No. 1998-19946, 100 g of red ginseng was hot-water extracted at 100 ° C. for 2 hours, and the extract was concentrated under reduced pressure (40% of water) to prepare a red ginseng extract.
실시예 2. 홍삼, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추, 감초 추출물의 제조 Example 2 Preparation of Red Ginseng, Angelica, Baekshou, Safflower Seed, Broiler, Astragalus, Jujube, Licorice Extract
당귀 3110g, 백하수오, 홍화씨, 육계, 황기, 대추 각각 1370g 및 감초 40g을 혼합하여 100℃에서 2시간 열수 추출하고 얻어진 추출액을 감압농축(수분 40%) 하고, 상기 농축액 41g과 실시예 1에서 제조된 홍삼 추출물 3g을 혼합하여 추출물을 제조하였다.Angelica 3110g, Baek Sewao, Safflower Seed, Broiler, Astragalus, Jujube, 1370g and 40g of Licorice, respectively, were mixed and extracted by hot water at 100 ° C for 2 hours, and the resulting extract was concentrated under reduced pressure (water content of 40%), and the concentrate was prepared in 41g and Example 1. 3 g of the red ginseng extract was mixed to prepare an extract.
비교예 1. 인삼 추출물의 제조 Comparative Example 1. Preparation of Ginseng Extract
인삼 100g을 100℃에서 2시간 열수 추출하고 얻어진 추출액을 감압농축(수분 40%) 하여 인삼 추출물을 제조하였다.100 g of ginseng was extracted with hot water at 100 ° C. for 2 hours, and the extract was concentrated under reduced pressure (40% of water) to prepare a ginseng extract.
실험예 1. 활성탄 식이 이동에 대한 효과Experimental Example 1. Effect on activated carbon dietary shift
변비 개선 효과를 평가하기 위하여 평균 체중 25 내지 28g의 발브씨(Balb/C) 웅성마우스(대한바이오링크, DMATD)를 실험동물로 하여 대조군과 시험군 각 군당 10마리씩 실험하였다. 시험군에는 상기 실시예 1, 2 및 비교예 1에서 제조된 생약 추출물을 3.2㎎/㎖ 농도로 식수에 녹여 3일간 투여한 후, 4일째 절식을 시키고, 절식 중에도 계속 투여하였다. 대조군은 시험군과 동일한 방법으로 실시하되 식수만 투여하였다. 5일째 시험군 및 대조군에 상기 실시예 1, 2 및 비교예 1에서 제조된 생약 추출물을 마리당 0.2㎖ 경구투여하고 1시간 후 활성탄(Sigma 사, 미국)과 아라비아검(Sigma 사, 미국)을 각 5% 및 10% 중량비로 혼합된 활성탄 식이를 0.2㎖를 경구투여한 후, 30분 뒤 희생시켜 위장관을 적출하여 활성탄 식이가 십이지장에서부터 회장(回腸)까지의 장관 거리 중 이동률을 조사하고 표 1에 나타내었다.In order to evaluate the effect of constipation, 10 rats in each group of the control group and the test group were tested using an average animal of 25-28 g of Valb / C male mice (Korean Biolink, DMATD). In the test group, the herbal extracts prepared in Examples 1, 2 and Comparative Example 1 were dissolved in drinking water at a concentration of 3.2 mg / ml, and then administered for 3 days, followed by fasting on the fourth day, and continued during fasting. The control group was administered in the same manner as the test group, but only drinking water was administered. On day 5, 0.2 ml orally of the herbal extracts prepared in Examples 1, 2 and Comparative Example 1 were administered orally to the test group and the control group on day 5, and activated carbon (Sigma, USA) and Arabian gum (Sigma, USA) were 1 hour later. 0.2 ml of the activated carbon diet mixed with 5% and 10% weight ratio was orally administered, and after 30 minutes, the gastrointestinal tract was extracted to investigate the rate of movement of the activated carbon diet in the intestinal distance from the duodenum to the ileum. Indicated.
[표 1]TABLE 1
상기 표 1에서 알 수 있는 바와 같이, 식수만 투여한 대조군에 비하여 실시예 1, 2 및 비교예 1의 시험군에서 전체적으로 활성탄 식이의 장 이동 효과가 증가하였으며, 비교예 1의 인삼추출물 투여군 보다 실시예 1의 홍삼 추출물 군에서 활성탄 식이의 장 이동 효과가 증가한 것을 알 수 있어, 만성변비를 개선하기 위하여 홍삼 추출물이 매우 유용할 것임을 확인할 수 있으며, 특히 실시예 2에서 예상보다도 뛰어난 증진된 효과가 나타내어 본 발명은 보다 증진된 홍삼 추출물의 변비 증상의 개선 기능을 갖는 것임을 알 수 있다.As can be seen in Table 1, the intestinal transfer effect of the activated carbon diet as a whole was increased in the test groups of Examples 1, 2 and Comparative Example 1 compared to the control group administered only drinking water, compared to the ginseng extract administration group of Comparative Example 1 In the red ginseng extract group of Example 1 it can be seen that the intestinal mobilization effect of the activated carbon diet, it can be seen that the red ginseng extract will be very useful to improve chronic constipation, especially in Example 2 shows an enhanced effect than expected It can be seen that the present invention has an improved function of constipation symptoms of the red ginseng extract more enhanced.
실험예2. 만성변비 개선 관능 평가Experimental Example 2. Chronic Constipation Improvement Sensory Evaluation
가. 시험군 선정end. Selection of test group
과거 12개월동안 최소한 12주 이상 변비 증상이 반복되거나 지속되는 만성변비 지원자 중에서 기질적 장질환이나 과거력이 있는 경우, 최근 1년간 심한 약 물 또는 알코올 남용 사실이 있는 경우, 과거 5년 이내에 악성 종양의 과거력이 있는 경우, 심한 심혈관계, 호흡관계, 신장, 간, 위장, 혈액, 신경계 및 정신질환이 있는 경우, 임신 및 수유 중인 여성, 및 위장관 운동 및 장의 감각에 영향을 주는 다른 약재를 정기적으로 사용하는 자를 제외하고, 만성변비의 이차원적인 원인을 배제하기 위하여 기본적인 혈액검사(CBC), 간기능검사(LFT), 및 소변검사(U/A)를 시행한 후 기본 검사상 정상인 자를 선별하여 각각 30명씩 실시예 1, 2 및 비교예 1의 3개 시험군으로 나누었다. 상기 지원자의 선별은 충남대학교 병원에서 실시하였다.Chronic constipation applicants with repeated or prolonged constipation symptoms for at least 12 weeks in the past 12 months have a history of organic bowel disease or history, and if there has been a severe drug or alcohol abuse in the past year, If you have a history of severe cardiovascular, respiratory, kidney, liver, gastrointestinal, blood, nervous and mental illness, pregnant and lactating women, and other medicines that affect gastrointestinal motility and intestinal sensation regularly In order to rule out the two-dimensional cause of chronic constipation, the basic blood test (CBC), liver function test (LFT), and urine test (U / A) were performed. The test was divided into three test groups of Examples 1, 2 and Comparative Example 1. The applicants were screened at Chungnam National University Hospital.
나. 만성변비 개선 여부 평가I. Evaluation of Chronic Constipation
상기 선정된 3개 시험군 각각 30명씩을 대상으로 하여 실시예 1, 2 및 비교예 1에서 제조된 추출물을 1일 2회 4주간 투여토록 하고 투여 전후를 비교하여 변비 증상별 개선 여부를 조사하여 만성변비 개선 효과를 표 2의 판정기준에 따라 판정(신뢰구간은 95%)하였으며 그 결과는 표 3에 나타내었다.To examine the improvement of constipation symptoms by comparing the before and after administration of the extract prepared in Examples 1, 2 and Comparative Example 1 twice a day for four weeks to 30 people each of the three selected test groups. Chronic constipation improvement effect was determined according to the criterion of Table 2 (95% confidence interval) and the results are shown in Table 3.
[표 2] 판정 기준Table 2 Judging Criteria
[표 3] 만성변비 개선 평가[Table 3] Evaluation of Chronic Constipation Improvement
상기 표 3에서 알 수 있는 바와 같이, 만성 변비환자를 대상으로 하는 관능 평가에서 비교예 1의 인삼 추출물을 투여한 시험군은 기대 이하의 결과를 나타냈으나, 실시예 1의 홍삼 추출물 투여군에서는 70% 이상 변비가 거의 소실된 것으로 나타내어 홍삼 추출물의 효능과 인삼 추출물의 효능의 차이를 확인 할 수 있을 뿐만 아니라, 특히, 홍삼의 증진된 만성변비 개선을 목적으로 하는 본 발명의 실시예 2에서는 매우 현저하게 개선된 것으로 나타났다.As can be seen in Table 3, the test group administered the ginseng extract of Comparative Example 1 in the sensory evaluation for chronic constipation patients showed less than expected results, 70 in the red ginseng extract administration group of Example 1 The constipation of more than% is almost disappeared to confirm the difference between the efficacy of the red ginseng extract and the efficacy of the ginseng extract, in particular, very remarkable in Example 2 of the present invention for the purpose of improving chronic constipation of red ginseng Has been improved.
그러므로 본 발명에 따른 홍삼, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물을 함유하는 생약 조성물은 보다 증진된 변비 증상의 개선 기능을 갖을 뿐만 아니라, 특히 만성변비 증상을 현저하게 개선시킬 수 있음을 확인할 수 있었다.Therefore, the herbal composition containing red ginseng, Angelica, baekshou, safflower seed, broiler, jujube, jujube and licorice extracts according to the present invention not only have a function of improving constipation symptoms, but also significantly improve chronic constipation symptoms. Could confirm.
다. 변비 증상별 개선 여부 평가All. Evaluation of improvement of constipation symptoms
5가지 변비 증상별 개선 내용은 다음과 같다.The five constipation symptoms are as follows.
(1) 배변 횟수(1) the number of bowel movements
상기 실시예 1, 2 및 비교예 1의 투여군 별에 대한 일주일간 평균 배변횟수를 조사한 결과를 다음 표 4에 나타내었다.The results of the examination of the average number of bowel movements per week for the administration groups of Examples 1, 2 and Comparative Example 1 are shown in Table 4 below.
[표 4]TABLE 4
표 4에서 알 수 있는 바와 같이, 비교예 1의 인삼 추출물을 투여한 시험군은 배변 횟수의 변화가 크지 않았으나, 실시예 1의 홍삼 추출물 투여군에서는 배변 횟수의 변화를 나타내어 홍삼 추출물은 만성변비 개선을 위한 건강기능식품 소재로 이용할 수 있음을 확인할 수 있으며, 특히 본 발명에 따른 실시예 2에서는 매우 현저하게 개선된 것으로 나타났다.As can be seen in Table 4, the test group administered the ginseng extract of Comparative Example 1 did not change the number of bowel movements significantly, but the red ginseng extract showed a change in the number of bowel movements in the red ginseng extract administration group of Example 1 to improve chronic constipation It can be seen that it can be used as a health functional food material, especially in Example 2 according to the present invention was found to be significantly improved.
그러므로 본 발명에 따른 홍삼, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물을 함유하는 생약 조성물은 보다 증진된 변비 증상의 개선 기능을 갖을 뿐만 아니라, 특히 만성변비 증상을 현저하게 개선시킬 수 있는 건강기능식품으로의 개발이 가능하다.Therefore, the herbal composition containing red ginseng, Angelica, baekshou, safflower seed, broiler, jujube, jujube and licorice extracts according to the present invention not only have a function of improving constipation symptoms, but also significantly improve chronic constipation symptoms. It is possible to develop into health functional food.
(2) 대변의 성상(2) the appearance of feces
상기 실시예 1, 2 및 비교예 1의 투여군 별에 대한 대변의 성상을 4가지 로 분류하여 조사하고 그 결과를 다음 표 5에 나타내었다.The characteristics of feces for each of the administration groups of Examples 1, 2 and Comparative Example 1 were classified into four and investigated. The results are shown in Table 5 below.
[표 5]TABLE 5
표 5에서 알 수 있는 바와 같이, 비교예 1의 인삼 추출물을 투여한 시험군은 변의 성상을 변화시키기는 했으나, 만성변비 증상을 개선시키기에는 크게 기대에 미치지 못하였다. 그러나 실시예 1의 홍삼 추출물 투여군에서는 만성변비 개선을 위한 건강기능식품 소재로 이용할 수 있음을 확인할 수 있으며, 특히 본 발명에 따른 실시예 2에서는 매우 현저하게 배변의 성상이 개선된 것을 확인할 수 있다.As can be seen in Table 5, the test group to which the ginseng extract of Comparative Example 1 was administered changed the appearance of the stool, but did not meet expectations significantly to improve the symptoms of chronic constipation. However, in the red ginseng extract administration group of Example 1 it can be seen that it can be used as a health functional food material for improving chronic constipation, especially in Example 2 according to the present invention it can be seen that the appearance of bowel movements significantly remarkably.
그러므로 본 발명에 따른 홍삼, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물을 함유하는 생약 조성물은 보다 증진된 변비 증상의 개선 기능을 갖을 뿐만 아니라, 특히 만성변비 증상을 현저하게 개선시킬 수 있음을 알 수 있다.Therefore, the herbal composition containing red ginseng, Angelica, baekshou, safflower seed, broiler, jujube, jujube and licorice extracts according to the present invention not only have a function of improving constipation symptoms, but also significantly improve chronic constipation symptoms. It can be seen that.
(3) 힘주기 빈도(3) power cycle frequency
상기 실시예 1, 2 및 비교예 1의 투여군 별에 대한 일주일간 평균 힘주기 빈도를 조사한 결과를 표 6에 나타내었다.Table 6 shows the results of investigating the weekly mean cycle frequency for each of the administration groups of Examples 1, 2 and Comparative Example 1.
[표 6]TABLE 6
표 6에서 알 수 있는 바와 같이, 비교예 1의 인삼 추출물을 투여한 시험군은 만성변비의 특징인 배변시의 힘주기 증상이 크게 개선되지 못했으나, 실시예 1의 홍삼 추출물 투여군에서는 만성변비 개선을 위한 건강기능식품 소재로 이용할 수 있음을 확인할 수 있으며, 특히 본 발명에 따른 실시예 2에서는 매우 현저하게 개선된 것을 확인할 수 있다.As can be seen in Table 6, the test group administered the ginseng extract of Comparative Example 1 did not significantly improve the strength symptoms during defecation, which is a characteristic of chronic constipation, the improvement of chronic constipation in the red ginseng extract administration group of Example 1 It can be seen that it can be used as a health functional food material, in particular in Example 2 according to the present invention can be seen that it is significantly improved.
(4) 폐쇄감의 빈도(4) frequency of feeling of obstruction
상기 실시예 1, 2 및 비교예 1의 투여군 별에 대한 일주일간 평균 폐쇄감의 빈도를 조사하고 그 결과를 표 7에 나타내었다.The frequency of the average closed feeling for the week for each administration group of Examples 1, 2 and Comparative Example 1 was investigated and the results are shown in Table 7.
[표 7]TABLE 7
표 7에서 알 수 있는 바와 같이, 비교예 1은 배변 후 폐쇄감 증상의 감소가 크게 향상되지 못했으나, 실시예 1, 2에서는 매우 현저하게 개선된 것을 확인할 수 있다. 특히, 만성변비환자의 습관적 폐쇄감을 해소할 수 있을 것으로 기대된다.As can be seen in Table 7, Comparative Example 1 was not significantly improved the reduction of the feeling of occlusion after bowel movement, it can be seen that in Example 1, 2 is significantly improved. In particular, it is expected to resolve the habitual obstruction of chronic constipation patients.
(5) 잔변감(5) residue
상기 실시예 1, 2 및 비교예 1의 투여군 별에 대한 잔변감 여부를 평가하여 그 결과를 표 8에 나타내었다.Example 1, 2 and Comparative Example 1 evaluated the residual feeling for each of the administration group according to the results are shown in Table 8.
[표 8]TABLE 8
표 8에서 알 수 있는 바와 같이, 실시예 1, 2 및 비교예 1 모두 잔변감은 개선되었으나, 만성변비 환자의 장관 내 숙변 등으로 크게 개선되지는 않았으나, 실시예 1, 2에서 홍삼 추출물은 만성변비 개선을 위한 건강기능식품 소재로 이용할 수 있음을 확인할 수 있으며, 특히 본 발명에 따른 실시예 2는 만성변비 증상을 개선하기 위한 건강기능식품으로 개발될 있음을 확인할 수 있었다.As can be seen in Table 8, the residual feeling was improved in Examples 1, 2 and Comparative Example 1, but the ginseng extract in chronic constipation patients was not significantly improved, but the red ginseng extract in Examples 1 and 2 was chronic constipation. It can be seen that it can be used as a health functional food material for improvement, in particular, Example 2 according to the present invention was confirmed that it can be developed as a health functional food for improving the symptoms of chronic constipation.
라. 부작용la. Side Effect
상기 선정된 3개 시험군 각각 30명씩을 대상으로 하여 투여 전후를 비교하여 부작용을 조사하였으나, 복용이 좋게 하기 위한 제제를 투여한 것이 아니어서 섭취하기 불편하였을 뿐 다른 부작용은 없는 것으로 조사되었다.Thirty patients in each of the three selected test groups were examined for side effects compared to before and after dosing.
이상과 같이 본 발명은 배변횟수의 증가, 대변의 성상, 힘주기의 빈도, 폐쇄감의 빈도 및 잔변감 등 모든 변비 증상에서 증상의 호전을 보여, 본 발명에 따른 홍삼은 만성변비 증상을 개선하기 위한 건강기능식품 소재로 이용할 수 있음을 확인할 수 있었으며, 특히 본 발명에 따른 홍삼, 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물을 함유하는 생약 조성물은 보다 증진된 변비 증상의 개선 기능을 갖는 건강기능식품으로의 개발이 가능한 것으로 평가되었다.As described above, the present invention shows the improvement of symptoms in all constipation symptoms, such as an increase in the number of bowel movements, the appearance of feces, the frequency of force cycles, the frequency of obstructive sensation, and residual feeling, the red ginseng according to the present invention is a health for improving the symptoms of chronic constipation It can be confirmed that it can be used as a functional food material, in particular, the herbal composition containing red ginseng, Angelica, Baekshou, safflower seed, broiler, Astragalus, jujube and licorice extract according to the present invention has an improved function of improving constipation symptoms It was evaluated that it could be developed as a dietary supplement.
<제조예 1> 음료의 제조Preparation Example 1 Preparation of Beverage
실시예 2에서 제조된 생약 조성물 44g, 샴피니온 추출물 분말 0.4g, 슈크랄로스 0.03g 및 혼합과일향(fruit mix flavor) 0.2g을 정제수를 가하여 전체 부피 300㎖를 제조하였다. 통상의 식품음료의 제조방법에 따라 약 1시간 동안 85℃에서 교반 가열하고 여과하여 음료를 제조하였다.44 g of the herbal composition prepared in Example 2, 0.4 g of champinion extract powder, 0.03 g of sucralose and 0.2 g of fruit mix flavor were added to purified water to prepare a total volume of 300 ml. According to the conventional method for preparing a food beverage, the beverage was prepared by stirring and heating at 85 ° C. for about 1 hour.
<제조예 2> 정제의 제조Preparation Example 2 Preparation of Tablet
실시예 2에서 제조된 생약 추출물을 분무건조하여 분말 100g, 유당 20g, 전분 150g, 결정셀룰로오즈 10g, 이노시톨 6g, 실리콘 알루민산나트륨 3g 및 식용색소 2.5g을 혼합하여 타정기로 정제를 제조하였다.The herbal extract prepared in Example 2 was spray-dried to prepare a tablet using a tablet press by mixing 100 g of powder, 20 g of lactose, 150 g of starch, 10 g of crystalline cellulose, 6 g of inositol, 3 g of sodium aluminate, and 2.5 g of food coloring.
따라서 본 발명은 인삼 추출물에 비하여 변비 개선 기능이 향상된 홍삼 추출 물을 건강기능식품의 소재로 이용할 수 있으며, 또한 본 발명은 홍삼 추출물에 당귀, 백하수오, 홍화씨, 육계, 황기, 대추 및 감초 추출물을 더 혼합하여 증진된 변비 개선 효과를 나타내는 건강기능식품을 제공한다.Therefore, the present invention can use the red ginseng extract improved constipation improvement function as a material of the health functional food as compared to the ginseng extract, and the present invention is the red ginseng extract, Angelica, Baek seshou, safflower seed, broiler, Astragalus, jujube and licorice extract It is further blended to provide a dietary supplement with improved constipation improvement.
특히, 본 발명은 만성변비 환자를 위한 건강기능식품으로의 개발이 가능하다.In particular, the present invention can be developed as a dietary supplement for chronic constipation patients.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050108050A KR100784169B1 (en) | 2005-11-11 | 2005-11-11 | healthy and functional food for constipation improvement |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050108050A KR100784169B1 (en) | 2005-11-11 | 2005-11-11 | healthy and functional food for constipation improvement |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070050624A true KR20070050624A (en) | 2007-05-16 |
KR100784169B1 KR100784169B1 (en) | 2007-12-10 |
Family
ID=38274098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050108050A KR100784169B1 (en) | 2005-11-11 | 2005-11-11 | healthy and functional food for constipation improvement |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100784169B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101034809B1 (en) * | 2011-03-03 | 2011-05-16 | 남영제약영농조합법인 | Method for producing red ginseng extract with enhanced saponin content and red ginseng extract produced by the same method |
CN103083504A (en) * | 2013-03-07 | 2013-05-08 | 于晓红 | Traditional medical composition for treating constipation |
KR101866915B1 (en) * | 2018-04-12 | 2018-06-12 | 조형권 | Manufacturing method for extracts granule of oriental herb medicine materials for improving constipation and extracts granule manufactured by the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980071887A (en) * | 1998-05-18 | 1998-10-26 | 이지은 | Health promotion tea |
KR100376307B1 (en) * | 2000-08-07 | 2003-03-17 | 한완석 | Healthy food composition for preventing and treatmenting constipation |
KR20020063734A (en) * | 2001-01-30 | 2002-08-05 | 주식회사 한국의과학연구소 | Drugs sampling method for nutrition and robustness |
KR100451665B1 (en) * | 2002-01-08 | 2004-10-08 | 추영진 | making method of health food, the chief ingredient is carthamus tinctorius seed, and the health food |
KR20040063430A (en) * | 2003-01-07 | 2004-07-14 | 한화수 | Natural composition for relieving constipation and method for preparing the same |
-
2005
- 2005-11-11 KR KR1020050108050A patent/KR100784169B1/en active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101034809B1 (en) * | 2011-03-03 | 2011-05-16 | 남영제약영농조합법인 | Method for producing red ginseng extract with enhanced saponin content and red ginseng extract produced by the same method |
CN103083504A (en) * | 2013-03-07 | 2013-05-08 | 于晓红 | Traditional medical composition for treating constipation |
KR101866915B1 (en) * | 2018-04-12 | 2018-06-12 | 조형권 | Manufacturing method for extracts granule of oriental herb medicine materials for improving constipation and extracts granule manufactured by the same |
Also Published As
Publication number | Publication date |
---|---|
KR100784169B1 (en) | 2007-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
KR20030059984A (en) | A new process for enhancing the efficacies of Ginseng and the uses of the Ginseng extract | |
CN110447902B (en) | Composition with weight-losing effect | |
CN105727205B (en) | Composition with weight-losing and blood fat-reducing effects and preparation method and application thereof | |
JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
KR100947278B1 (en) | A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof | |
CN112006137A (en) | Spleen-tonifying and stomach-nourishing Su-radish tea and preparation method thereof | |
KR100597235B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
CN104208224B (en) | A kind of broiler compound traditional Chinese medicine composite and its preparation method and application | |
KR100784169B1 (en) | healthy and functional food for constipation improvement | |
KR20130009901A (en) | Health food composition for improving blood circulation, strengthening energy and preventing osteoporosis | |
KR101228920B1 (en) | A composition comprising of a leaf extract of dendropanax morbifera for treating and preventing intestinal function disorder | |
KR102014922B1 (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
KR102045847B1 (en) | Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin | |
KR101668447B1 (en) | Composition for curing hanover and health functional foods composition comprising the same | |
CN1927298A (en) | Traditional Chinese medicine preparation for treating stomach and intestinal disease and its preparation | |
KR20200061446A (en) | Food composition using the salicornia herbacea and method for producing the same | |
KR20210041387A (en) | A natural tea removing the effect of hangover contained the extract material in arrowroot blossoms and Plantago ovata | |
KR20020074905A (en) | Constituents for herbal healthy food containing radish extracts | |
CN1262297C (en) | Chinese medicine for treating irritable bowel syndrome and preparing method thereof | |
CN108904694A (en) | It is a kind of for improving immune oyster Chinese yam particle and preparation method thereof | |
KR100538983B1 (en) | Pharmaceutical composition comprising the crude drug extract for improving liver function | |
KR20170103602A (en) | Composition of the extract of combined herb including the peel extract of mandarin fructus for preventing and treating constipation | |
KR20230159775A (en) | Composition having the effect of improving childhood obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Publication of correction | ||
FPAY | Annual fee payment |
Payment date: 20121127 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131125 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141121 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151130 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161130 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171128 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20191114 Year of fee payment: 13 |